Gujarat Kidney And Super Speciality Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
GKSL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gujarat Kidney and Super Speciality Limited filed its unaudited standalone and consolidated financial results for Q2 FY26 and H1 FY26 (ended September 30, 2025). On a standalone basis, Q2 revenue from operations fell to ₹964.26 lakh from ₹1,144.99 lakh a year ago (a drop of roughly 16%), while Q2 profit after tax declined to ₹230.12 lakh from ₹389.98 lakh (down about 41%). For the half-year, standalone revenue grew to ₹2,109.25 lakh (vs ₹1,867.05 lakh) and PAT rose to ₹620.10 lakh (vs ₹563.13 lakh). On a consolidated basis, H1 PAT jumped to ₹827.96 lakh from ₹563.14 lakh, helped by subsidiaries and controlled entities. The statutory auditor Y. M. Shah & Co. issued an unmodified limited review report on both standalone and consolidated results.
The picture is mixed for shareholders: Q2 performance weakened sharply on both revenue and profit, but H1 numbers are still in growth territory, and the consolidated bottom line is up nearly 47% YoY. A key red flag is the negative operating cash flow on both standalone (₹823 lakh outflow) and consolidated (₹736 lakh outflow) levels despite healthy reported profits, suggesting working capital is stretching — investors should watch receivables and cash collection closely in upcoming quarters.